Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 1999-01-01 / Gene Ther. 1999 Jan;6(1):63-73A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 1998-12-01 / Mol. Med. 1998 Dec;4(12):783-94Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus
/in International Publications, Newcastle Disease Virus /von 1998-12-01 / Int. J. Oncol. 1998 Dec;13(6):1105-15Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
/in Breast Cancer, International Publications, Newcastle Disease Virus, Ovarian Cancer /von 1997-04-01 / J. Clin. Oncol. 1997 Apr;15(4):1354-66Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy
/in International Publications, Newcastle Disease Virus, Soft Tissue Sarcoma /von 1994-12-01 / Cancer Res. 1994 Dec;54(23):6017-21A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate
/in International Publications, Newcastle Disease Virus /von 1992-01-01 / Med Oncol Tumor Pharmacother 1992;9(4):169-71A critical look at the subluxation hypothesis
/in International Publications, Newcastle Disease Virus /von 1989-04-01 / J Manipulative Physiol Ther 1989 Apr;12(2):152-5A preliminary investigation of the parallelogram concept in genetic monitoring and risk estimation
/in International Publications, Newcastle Disease Virus /von 1986-01-01 / Prog. Clin. Biol. Res. 1986;207:203-15
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Interview mit Prof. Dr. Volker Schirrmacher im Klassik Radio
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum